MORPHOLOGICAL CHANGES IN TISSUES AND CELLS OF THE IMMUNE SYSTEM RESULTING FROM CHEMICAL THERAPY
Keywords:
In particular, morphological changes occurring in the organs of the immune system - the thymus gland, lymph nodes, and bone marrow - weaken the body's overall defense capabilities and reduce resistance to infections.Abstract
It is currently known that the types of cytostatic therapy widely used in the treatment of oncological diseases have a negative impact not only on tumor cells but also on physiological tissues.
References
1. Stacheeva M.N., Eidenzon D., Slonimskaya E.M. et al. The relationship between the state of the immune system as an integrated whole and the clinical course of breast cancer // Siberian Oncological Journal. 2011. No. 2 (44). PP. 11-19.
2. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy – review of a new approach // Pharmacol. Rev. 2003. Vol. 55 (2). P. 241–269.
3. Bacacs T., Mehrishi J.N. Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering? // BMC Cancer. 2010. Vol. 10. P. 251–256. 11. Beasley G.M., Olson J.A. Jr. What’s new in neoadjuvant therapy for breast cancer? // Adv. Surg. 2010. Vol. 44. P. 199–228.
4. Swann J.B., Smyth M.J. Immune surveillance of tumors // J Clin Invest. – 2007. – Vol. 117, No. 5. – P. 1137– 1146.
5. Rezaei N., Hedayat M., Aghamohammadi A., Nichols K.E. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies // J Allergy Clin Immunol. – 2011. – Vol. 127, No. 6. – P. 1329–1341.
6. Engels E.A., Pfeiffer R.M., Fraumeni J.F. Jr. et al. Spectrum of cancer risk among US solid organ transplant recipients // JAMA. – 2011. – Vol. 306, No. 17. – P. 1891–1901.
7. Teng M.W., Galon J., Fridman W.H., Smyth M.J. From mice to humans: developments in cancer immunoediting // J Clin Invest. – 2015. – Vol. 125, No. 9. – P. 3338–3346.
8. Gubin M.M., Artyomov M.N., Mardis E.R., Schreiber R.D. Tumor neoantigens: building a framework for personalized cancer immunotherapy // J Clin Invest. – 2015. – Vol. 125, No. 9. – P. 3413–3421.
